Nima Melzer

676 total citations
24 papers, 519 citations indexed

About

Nima Melzer is a scholar working on Immunology, Cardiology and Cardiovascular Medicine and Internal Medicine. According to data from OpenAlex, Nima Melzer has authored 24 papers receiving a total of 519 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Immunology, 10 papers in Cardiology and Cardiovascular Medicine and 9 papers in Internal Medicine. Recurrent topics in Nima Melzer's work include Psoriasis: Treatment and Pathogenesis (12 papers), Venous Thromboembolism Diagnosis and Management (9 papers) and Atrial Fibrillation Management and Outcomes (8 papers). Nima Melzer is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (12 papers), Venous Thromboembolism Diagnosis and Management (9 papers) and Atrial Fibrillation Management and Outcomes (8 papers). Nima Melzer collaborates with scholars based in Germany, Switzerland and United States. Nima Melzer's co-authors include Christian Sieder, Sylvia Haas, Diamant Thaçi, L. Heilmann, Georg–Friedrich von Tempelhoff, B. Kemkes‐Matthes, Ajay K. Kakkar, Mathias Freund, David F. Heigener and Kristian Reich and has published in prestigious journals such as Journal of Investigative Dermatology, Nutrients and British Journal of Dermatology.

In The Last Decade

Nima Melzer

24 papers receiving 510 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nima Melzer Germany 9 267 206 155 133 100 24 519
André van Rij New Zealand 11 28 0.1× 149 0.7× 62 0.4× 43 0.3× 59 0.6× 20 527
Taufiq Salahuddin United States 10 258 1.0× 22 0.1× 123 0.8× 47 0.4× 3 0.0× 21 461
Siavash Piran Canada 14 17 0.1× 405 2.0× 341 2.2× 6 0.0× 58 0.6× 27 650
Jean-Luc Labourey France 9 31 0.1× 50 0.2× 31 0.2× 24 0.2× 45 0.5× 24 275
Francesco Bondanini Italy 12 30 0.1× 9 0.0× 23 0.1× 28 0.2× 13 0.1× 29 343
Antonio Gidaro Italy 10 27 0.1× 21 0.1× 49 0.3× 5 0.0× 39 0.4× 55 283
Hermes Velásquez United States 5 86 0.3× 121 0.6× 94 0.6× 2 0.0× 6 0.1× 7 443
Giorgia Saccullo Italy 13 74 0.3× 236 1.1× 183 1.2× 68 0.7× 23 427
Geneviève Freyburger France 12 34 0.1× 252 1.2× 273 1.8× 3 0.0× 27 0.3× 31 632
Tatiana Mularek‐Kubzdela Poland 15 9 0.0× 154 0.7× 338 2.2× 6 0.0× 27 0.3× 66 563

Countries citing papers authored by Nima Melzer

Since Specialization
Citations

This map shows the geographic impact of Nima Melzer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nima Melzer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nima Melzer more than expected).

Fields of papers citing papers by Nima Melzer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nima Melzer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nima Melzer. The network helps show where Nima Melzer may publish in the future.

Co-authorship network of co-authors of Nima Melzer

This figure shows the co-authorship network connecting the top 25 collaborators of Nima Melzer. A scholar is included among the top collaborators of Nima Melzer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nima Melzer. Nima Melzer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Augustin, Matthias, Dennis Häckl, Regina Hampel, et al.. (2024). The socio‐economic burden of H1‐antihistamine‐refractory chronic spontaneous urticaria in Germany. Journal of the European Academy of Dermatology and Venereology. 38(11). 2102–2109. 3 indexed citations
2.
Loser, Karin, Dieter Metze, Nima Melzer, et al.. (2024). Secukinumab Reduces Psoriasis-associated Pruritus and Regenerates the Cutaneous Nerve Architecture: Results from PSORITUS a Doubleblind, Placebo-controlled, Randomized Withdrawal Phase IIIb Study. Acta Dermato Venereologica. 104. adv40737–adv40737. 1 indexed citations
3.
4.
Schwarz, Peter E. H., et al.. (2019). ERAPSO: Revealing the High Burden of Obesity in German Psoriasis Patients. Dermatology and Therapy. 9(3). 579–587. 11 indexed citations
5.
Thaçi, Diamant, Andreas Körber, Ralph von Kiedrowski, et al.. (2019). Secukinumab is effective in treatment of moderate‐to‐severe plaque psoriasis: real‐life effectiveness and safety from the PROSPECT study. Journal of the European Academy of Dermatology and Venereology. 34(2). 310–318. 27 indexed citations
6.
Stebut, Esther von, Kristian Reich, Diamant Thaçi, et al.. (2018). Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks. Journal of Investigative Dermatology. 139(5). 1054–1062. 174 indexed citations
7.
Stebut, Esther von, Kristian Reich, Diamant Thaçi, et al.. (2018). Secukinumab Reduces Endothelial Dysfunction in Subjects with Moderate-to-Severe Plaque Psoriasis Over 52 Weeks: Results of the Exploratory CARIMA Study. SKIN The Journal of Cutaneous Medicine. 2. S20–S20. 1 indexed citations
8.
Reich, Kristian, Christian Sieder, Teresa Bachhuber, Nima Melzer, & Michael Sticherling. (2017). 009 PASI ≤ 2 corresponds to PASI 90, irrespective of baseline severity: A post-hoc analysis of the PRIME-study. Journal of Investigative Dermatology. 137(10). S194–S194. 1 indexed citations
9.
Körber, Andreas, Diamant Thaçi, Ralph von Kiedrowski, et al.. (2017). Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real‐life data of prior and concomitant use of psoriasis treatments from the PROSPECT study. Journal of the European Academy of Dermatology and Venereology. 32(3). 411–419. 13 indexed citations
10.
Augustin, Matthias, et al.. (2016). Cost-Effectiveness of Secukinumab as First Biologic Treatment for Psoriasis Compared with Initiating Other Biologic Therapy in Germany. Value in Health. 19(7). A568–A569. 2 indexed citations
11.
Krieter, Detlef H., et al.. (2015). Pharmacokinetics of Certoparin During In Vitro and In Vivo Dialysis. Artificial Organs. 39(11). 951–959. 2 indexed citations
12.
Riess, Hanno, et al.. (2014). Treatment of deep vein thrombosis in patients with pulmonary embolism. Blood Coagulation & Fibrinolysis. 25(8). 838–844. 2 indexed citations
13.
14.
Eiselé, R., Nima Melzer, & Peter Bramlage. (2014). Perioperatives Gerinnungsmanagement bei oraler Antikoagulation. Der Chirurg. 85(6). 513–519. 8 indexed citations
15.
Bramlage, Peter, et al.. (2012). Comparison of 3,000 and 5,000 IU aXa/day certoparin in the prevention of deep-vein thrombosis after total hip replacement. Thrombosis Journal. 10(1). 10–10. 6 indexed citations
16.
17.
Krieter, Detlef H., Horst‐Dieter Lemke, Stefan Fischer, et al.. (2012). A multi-center, prospective, open-label, 8-week study of certoparin for anticoagulation during maintenance hemodialysis – the membrane study. BMC Nephrology. 13(1). 50–50. 12 indexed citations
18.
Spannagl, Michael, et al.. (2012). Prospective, Non-interventional Study on the Real-World Use of Certoparin in Daily Practice—The PROMEMBER Study. Clinical and Applied Thrombosis/Hemostasis. 19(1). 86–91. 5 indexed citations
19.
Haas, Sylvia, Sebastian Schellong, Ulrich Tebbe, et al.. (2011). Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY. BMC Cancer. 11(1). 316–316. 31 indexed citations
20.
Schellong, Sebastian, H. Gerlach, Ulrich Tebbe, et al.. (2011). Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: An analysis of the CERTIFY study. Thrombosis Research. 128(5). 417–421. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by André van Rij Breakdown of academic impact, for papers by Taufiq Salahuddin Breakdown of academic impact, for papers by Siavash Piran Breakdown of academic impact, for papers by Jean-Luc Labourey Breakdown of academic impact, for papers by Francesco Bondanini Breakdown of academic impact, for papers by Antonio Gidaro Breakdown of academic impact, for papers by Hermes Velásquez Breakdown of academic impact, for papers by Giorgia Saccullo Breakdown of academic impact, for papers by Geneviève Freyburger Breakdown of academic impact, for papers by Tatiana Mularek‐Kubzdela
Rankless by CCL
2026